Rodman & Renshaw assumed coverage on StemCells (NASDAQ: STEM) with a Buy rating and a price target of $1.50.Analyst Raghuram ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE